Mersana Therapeutics, Inc. (MRSN) EPS Estimated At $-0.58; 1 Analysts Bullish Carpetright plc (LON:CPR)

July 18, 2018 - By Mike Johnson

Carpetright plc (LON:CPR) Logo

Analysts expect Mersana Therapeutics, Inc. (NASDAQ:MRSN) to report $-0.58 EPS on August, 10.They anticipate $5.75 EPS change or 90.84% from last quarter’s $-6.33 EPS. After having $-0.54 EPS previously, Mersana Therapeutics, Inc.’s analysts see 7.41% EPS growth. The stock increased 2.63% or $0.42 during the last trading session, reaching $16.41. About 176,200 shares traded or 44.85% up from the average. Mersana Therapeutics, Inc. (NASDAQ:MRSN) has 0.00% since July 18, 2017 and is . It has underperformed by 12.57% the S&P500. Some Historical MRSN News: 28/03/2018 – MERSANA THERAPEUTICS INC – ENROLLMENT ON TRACK FOR PHASE 1 TRIAL OF XMT-1522 PATIENTS WITH ADVANCED TUMORS EXPRESSING HER2; 13/04/2018 – Mersana Therapeutics Presenting at Conference Tomorrow; 25/05/2018 – IMFINZI® (Durvalumab) Significantly Improves Overall Survival in the Phase lll Pacific Trial for Unresectable Stage lll Non-Small Cell Lung Cancer; 22/05/2018 – Mersana Therapeutics to Present Interim Phase 1 Data on XMT-1522 at the 2018 American Society of Clinical Oncology Annual Meeting; 28/03/2018 – MERSANA THERAPEUTICS – EXPECTS CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES WILL ENABLE CO TO FUND OPERATING PLAN THROUGH AT LEAST MID-2019; 23/03/2018 – INNATE PHARMA SA – PARTNER MEDIMMUNE EXPANDS COLORECTAL CANCER PATIENT COHORT IN ONGOING PHASE l TRIAL EVALUATING MONALIZUMAB IN COMBINATION WITH IMFINZI® (DURVALUMAB); 21/03/2018 – Mersana Therapeutics to Host Conference Call Announcing Fourth Quarter and Full Year 2017 Financial Results and Business; 25/05/2018 – IMFINZI(R) (Durvalumab) Significantly Improves Overall Survival in the Phase III Pacific Trial for Unresectable Stage III Non-Small Cell Lung Cancer; 19/03/2018 – Mersana Strengthens Board of Directors Leadership with Appointment of Willard H. Dere, M.D., Professor at the University of Uta; 07/05/2018 – Mersana Therapeutics at Deutsche Bank Conference Tomorrow

Among 3 analysts covering Carpetright PLC (LON:CPR), 1 have Buy rating, 0 Sell and 2 Hold. Therefore 33% are positive. Carpetright PLC had 13 analyst reports since January 19, 2018 according to SRatingsIntel. The firm earned “Hold” rating on Thursday, April 12 by Shore Capital. The company was downgraded on Friday, January 19 by Peel Hunt. Shore Capital maintained the shares of CPR in report on Tuesday, June 12 with “Hold” rating. The stock of Carpetright plc (LON:CPR) earned “Hold” rating by Peel Hunt on Thursday, March 1. Peel Hunt upgraded Carpetright plc (LON:CPR) rating on Tuesday, June 26. Peel Hunt has “Buy” rating and GBX 40 target. The firm earned “Hold” rating on Friday, May 18 by Shore Capital. Shore Capital maintained the shares of CPR in report on Thursday, March 1 with “Hold” rating. On Monday, January 22 the stock rating was maintained by Deutsche Bank with “Hold”. Deutsche Bank maintained it with “Hold” rating and GBX 65 target in Friday, March 2 report. Shore Capital maintained the shares of CPR in report on Friday, May 11 with “Hold” rating. See Carpetright plc (LON:CPR) latest ratings:

26/06/2018 Broker: Peel Hunt Rating: Buy Old Target: GBX 70.00 New Target: GBX 40.00 Upgrade
26/06/2018 Broker: Shore Capital Rating: Hold Maintain
12/06/2018 Broker: Shore Capital Rating: Hold Maintain
18/05/2018 Broker: Shore Capital Rating: Hold Maintain
11/05/2018 Broker: Shore Capital Rating: Hold Maintain
27/04/2018 Broker: Shore Capital Rating: Hold Old Target: GBX 42.00 New Target: GBX 42.00 Maintain
12/04/2018 Broker: Shore Capital Rating: Hold New Target: GBX 42.00 Maintain
02/03/2018 Broker: Deutsche Bank Rating: Hold Old Target: GBX 95.00 New Target: GBX 65.00 Maintain
01/03/2018 Broker: Peel Hunt Rating: Hold Old Target: GBX 100.00 New Target: GBX 70.00 Maintain
01/03/2018 Broker: Shore Capital Rating: Hold Maintain

The stock increased 1.20% or GBX 0.35 during the last trading session, reaching GBX 29.55. About 24,997 shares traded. Carpetright plc (LON:CPR) has 0.00% since July 18, 2017 and is . It has underperformed by 12.57% the S&P500.

Carpetright plc engages in the retail sale of floor coverings and beds. The company has market cap of 89.66 million GBP. The firm also sells its products through online. It currently has negative earnings. It operates 564 stores in the United Kingdom, Belgium, the Netherlands, and the Republic of Ireland.

Mersana Therapeutics, Inc. is a biotechnology firm that discovers, engineers, and develops antibody drug conjugates to cure various cancers. The company has market cap of $375.82 million. The firm develops immune conjugate therapies to create drugs that enhance patientsÂ’ lives. It currently has negative earnings. It offers XMT-1522, a drug therapy for tumor models that express relatively low amounts of the HER2 protein; and human anti-HER2 antibody used in XMT-1522.

Another recent and important Mersana Therapeutics, Inc. (NASDAQ:MRSN) news was published by Benzinga.com which published an article titled: “7 Stocks To Watch For July 3, 2018” on July 03, 2018.

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.